Erythromycin shortage — AU supply status & alternatives

Erythromycin

ATC D10AF02

🇦🇺 AUST R 48287 · Alphapharm Pty Ltd

In shortage · Australia

Eritromicina IdiERYC erythromycin ERYTHROCIN IV erythromycinErythromycin Topical Solution USP, 2%Erythromycin Topical Gel USP, 2%, Net Wt+1 more

In declared shortage · 🇦🇺 Australia & also short in🇨🇦 CA🇺🇸 US🇩🇪 DE🇧🇪 BE

Critical shortage

Product discontinued / no longer available on the Australian market.

Reading today’s signals…

🇦🇺 AUAEMPA$4.46DPMQ A$22.22details →

• Can I substitute?

No pathway on record

prescriber decision required

⇄ Best alternative

None listed

refer to prescriber

◷ Expected back

July 2025

Sponsor est. via TGA — may differ by brand

Product attributes reference data we hold

Active ingredient (INN)	Erythromycin
Brand names	Eritromicina Idi, ERYC erythromycin, ERYTHROCIN IV erythromycin, Erythromycin Topical Solution USP, 2%, Erythromycin Topical Gel USP, 2%, Net Wt, ERYTHROMYCIN OPHTHALMIC OINTMENT USP 0.5%, Net Weight:
ATC level 5	D10AF02
ATC level 4	D10AF
Therapeutic category	Auto-created by Therapeutic Goods Administration — Medicine Shortages scraper
WHO Essential Medicine	Yes (2023)
Controlled substance	No
Marketing-authorisation holders	Alphapharm Pty Ltd, PINEWOOD LABORATORIES LIMITED, WAYMADE PLC, FLYNN PHARMA LIMITED +9 more
Registrations on file	24
Patient information leaflet (PIL)	Not on file
Summary of product characteristics (SPC)	Not on file

Trade price 🇦🇺 PBS · July 2026

🇦🇺 AU

● Official price on file

Ex-manufacturer

A$4.46

AEMP

Dispensed (DPMQ)

A$22.22

incl. fees

Pack

erythromycin (as ethylsuccinate) 200 mg/5 mL powder for oral liquid, 100 mL

Source: PBSEffective July 2026 · AUD

Other markets

🇬🇧 GB

£2.06

Drug Tariff

🇺🇸 US

US$1.74

Acquisition

🇪🇸 ES

€3.75

Retail price

Substitution pathways 🇦🇺 Australia · TGA

—

No substitution instrument in force

Dispense per normal rules, or refer to the prescriber. No active SSSI/S19A instrument detected for this medicine.

Global API supply base 🇺🇸 FDA Drug Master Files · active Type II

16 API manufacturers

Manufacturers with an active Type II Drug Master File — i.e. cleared to supply this active ingredient into the US market. A proxy for how concentrated the global manufacturing base is.

Low concentration risk

Sm Biomed Sdn BhdErcros SAPolfa TarchominAbbvie INCXian Lijun Pharmaceutical CO LTDHec Pharm CO LTD+10 more

Manufacturing countries: Malaysia, Spain, United States, China, India · Source: FDA List of Drug Master Files

FDA-approved products 🇺🇸 Drugs@FDA

Approved applications

Generic (ANDA)

Brand (NDA/BLA)

Mar 2023

Latest approval

Shortage status by regulator official notices

🇦🇺

Australia

TGA · just now

Critical

🇨🇦

Canada

HC · 7h ago

High

🇧🇪

FAMHP · 2d ago

High

🇺🇸

United States

FDA MedWatch · 2mo ago

High

🇩🇪

Germany

BfArM · 12d ago

Medium

🇸🇬

Singapore

HSA-SG · 4mo ago

Resolved

Recalls official enforcement reports

🇺🇸

ERYTHROMYCIN

Zydus Pharmaceuticals (USA) Inc · Apr 2026

Class IIdetails ↗

🇺🇸

ERYTHROMYCIN

Zydus Pharmaceuticals (USA) Inc · Apr 2026

Class IIdetails ↗

🇺🇸

Erythromycin

Synergy Rx · Feb 2017

Class IIdetails ↗

Verified timeline regulator events

🇧🇪 20 May 2026

high reported

🇩🇪 7 Jan 2026

medium reported

🇩🇪 19 Dec 2025

medium reported

🇸🇬 3 Dec 2025

Shortage resolved

🇨🇦 23 July 2025

high reported

🇦🇺 30 Apr 2025

critical reported

Sources official regulators

🇦🇺

TGA

verified just now

verify ↗

🇨🇦

verified 7h ago

verify ↗

🇧🇪

FAMHP

verified 2d ago

verify ↗

🇩🇪

BfArM

verified 12d ago

verify ↗

🇺🇸

FDA MedWatch

verified 2mo ago

verify ↗

🇸🇬

HSA-SG

verified 4mo ago

verify ↗

Registration recordmarketing-authorisation holders

Registrations & marketing-authorisation holders24 registrations · 13 MA holders

Product	Strength	Form	Market	MA holder	Status
E-Mycin	400mg	—	🇦🇺 AU	Alphapharm Pty Ltd	Active
Erythromycin Ethylsuccinate	125MG	suspension	🇬🇧 GB	PINEWOOD LABORATORIES LIMITED	Active
Erythromycin Ethylsuccinate	250 MG	suspension	🇬🇧 GB	PINEWOOD LABORATORIES LIMITED	Active
Erythromycin Ethylsuccinate	500 MG	suspension	🇬🇧 GB	PINEWOOD LABORATORIES LIMITED	Active
ERYTHROMYCIN 125 MG/5ML SUGAR FREE GRANULES FOR ORAL SUSPENSION	125 MG	suspension	🇬🇧 GB	PINEWOOD LABORATORIES LIMITED	Active
ERYTHROMYCIN 250 MG/5ML SUGAR FREE GRANULES FOR ORAL SUSPENSION	250 MG	suspension	🇬🇧 GB	PINEWOOD LABORATORIES LIMITED	Active
Erythromycin Tablets Bp	250MG	tablet	🇬🇧 GB	WAYMADE PLC	Active
ERYTHROMYCIN 1G POWDER FOR CONCENTRATE FOR SOLUTION FOR INFUSION	1G	solution	🇬🇧 GB	FLYNN PHARMA LIMITED	Active
ERYTHROMYCIN 250MG GASTRO-RESISTANT TABLETS	250MG	tablet	🇬🇧 GB	BRISTOL LABORATORIES LIMITED	Active
Erythromycin Ethylsuccinate Granules For	125MG	suspension	🇬🇧 GB	Aurobindo Pharma Limited	Active
Erythromycin Ethylsuccinate Granules For	250MG	suspension	🇬🇧 GB	Aurobindo Pharma Limited	Active
Erythromycin Ethylsuccinate Granules For	500MG	suspension	🇬🇧 GB	Aurobindo Pharma Limited	Active
ERYTHROMYCIN 250 MG TABLETS	250 MG	tablet	🇬🇧 GB	MILPHARM LIMITED	Active
Erythromycin Ethylsuccinate Sf	125MG	erythromycin	🇬🇧 GB	AMDIPHARM UK LIMITED	Active
Erythromycin Ethylsuccinate Sf	250MG	erythromycin	🇬🇧 GB	AMDIPHARM UK LIMITED	Active

+9 more registrations on file

Mederti Drug Report

Generated 4 July 2026 · Australia market · 6 regulatory sources

For health-professional reference only. Mederti aggregates shortage and substitution information from official regulatory sources. It is not clinical advice and data may be incomplete or delayed. Confirm any substitution or supply decision against the primary regulator source, the prescriber, and current clinical references (e.g. AMH) before acting. Terms.